The Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma

Status: Withdrawn
Intervention Type: Procedure, Drug, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This pilot clinical trial studies the correlation between the genetics and brain images of patients with newly diagnosed glioblastoma before surgery. The genetic characteristics of a tumor are an important way to predict how well it will respond to treatment. Imaging, using magnetic resonance imaging (MRI), takes detailed pictures of organs inside the body, and may also provide information that helps doctors predict how brain tumors will respond to treatment. If MRI can provide doctors with similar information about the tumor as the tumor's genes, it may be able to be used to predict tumor response in patients whose tumors cannot be reached by surgery or biopsy to get tissue samples.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: No
View:

• Patients who will be undergoing surgery for newly-diagnosed glioblastoma

• Subtotal, gross total or biopsy patients will be eligible

• Confirmation of pathology as glioblastoma

Time Frame
Start Date: March 20, 2016
Completion Date: October 26, 2017
Treatments
Experimental: Diagnostic (MRI, tumor tissue analysis)
Patients undergo MRI before and after gadolinium contrast administration, including 3D volumetric T1-weighted sequence, FLAIR sequence, diffusion weighted imaging, and perfusion MRI. Tissue samples are also analyzed for the tumor genetic profile.
Authors
Pierre Giglio, Joseph Helpern
Sponsors
Leads: Ohio State University Comprehensive Cancer Center

This content was sourced from clinicaltrials.gov

Similar Clinical Trials